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Introduction: Organ donation after circulatory death (DCD) has become an accepted strategy to reduce the
shortage of organs for transplantation in many European countries. The use and number of DCD donors varies
between countries. The purpose of this study was to evaluate the available protocols for DCD in Europe.
Methods: We contacted national transplant societies and responsible transplant co-ordinators in the countries that
perform DCD to obtain DCD protocols. We compared information on the protocols and additional data including:
inclusion and exclusion criteria for donation, legislation, determination of death and preservation methods.
Results: In ten European countries DCD is performed, eight of which describe the methods in protocols. There are
large differences in used DCD categories, legislation and the way death is determined. Protocols differ in the detail
in which DCD procedures are described and the way methods are supported by additional consensus statements
and ethical frameworks.
Conclusions: Although DCD is an established strategy to enlarge the donor pool and to contribute to the
reduction of the waiting list for transplantation, its potential has not been fully utilized yet. To further promote DCD
transplantation, it is important to share expertise and obtain consensus, so that this can be translated into more
uniform and solid protocols supported by the competent authorities, transplant and intensive care professionals,
which may eventually result in a further promotion of DCD transplantation in Europe.Introduction
Kidney transplantation increases life expectancy and
quality of life in patients with end-stage renal disease
compared with renal dialysis [1,2]. However, there is an
ongoing universal shortage of donor organs to meet the
demand for transplantation, and organ donation and
transplantation rates vary widely across countries. The
World Health Organization published guiding principles
on human cell, tissue and organ transplantation to sup-
port countries in taking responsibility for progression to
self-sufficiency for the organ donation and transplant-
ation needs of their people [3].
One way to expand the organ donor pool is the use of
organs from donors who die after circulatory death
(DCD). These organs are inevitably subjected to a period
of warm ischemia, which adversely affects transplant
outcome [4]. Despite the higher incidence of primary
nonfunction and delayed graft function, transplantation* Correspondence: t.wind@mumc.nl
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reproduction in any medium, provided the orof DCD kidneys is associated with increased recipient
survival compared with staying on the transplant waiting
list with the option of later receiving a conventional kidney
from donation after brain death (DBD) [5]. Procurement
of kidneys from DCD donors holds the potential to expand
the donor pool 2.5 to 4 times [6].
Next to DCD kidney transplantation, which has been a
generally accepted source of donor organs in many coun-
tries, DCD transplantation of the liver, lung and pancreas
is possible and has been increasingly performed in the
past decade. The results of DCD liver transplantation are
comparable with DBD liver transplantation, with equiva-
lent 1-year and 3-year graft survival and patient survival,
although there is a higher risk of biliary strictures in DCD
livers [7]. The number of DCD lung transplantations is
still relatively low; a number of transplant centers show
equivalent outcomes for DCD and DBD lung transplant-
ation. DCD lung transplantation offers a good opportunity
to reduce the donor lung shortage [8]. The DCD potential
is still not fully used, despite the fact that DCD has proven
to be effective to expand the donor pool. In contrast totd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and the percentage of DCD donors out of the total num-
ber of deceased donors varies largely.
In 1995, at the First International Workshop on Non-
heart Beating Donation in Maastricht, four categories of
nonheart-beating donation were identified, which in-
clude controlled and uncontrolled donors (Table 1) [9].
Nomenclature has changed since then, from nonheart-
beating donation to donation after cardiac death, to
make a more clear difference between cardiac death and
brain death. Recently, donation after circulatory death
has been proposed as the nomenclature of choice.
Depending on the category, the donor procedure is
carried out in the emergency room, in the ICU or in the
operating room. The popularization of DCD has caused
a growing demand for protocols that describe donor
management and preservation strategies. Furthermore,
ethical aspects of DCD are essential and have to be
addressed [10,11].
The aim of this study is to evaluate European DCD
protocols, focusing on the inclusion and exclusion cri-
teria for organ donation, legislation on DCD donation,
determination of death and preservation methods for
organ procurement. Although protocols do not always
completely reflect the actual clinical practice and often
small violations of the protocols are present, this evalu-
ation may provide a general overview of the European
attitude towards DCD. It is important to obtain an over-
all understanding of the different approaches to DCD in
Europe and to evaluate whether there is room for
improvement.
Materials and methods
There are currently 10 countries in Europe with an ac-
tive DCD program [12]. Between January 2011 and Janu-
ary 2012 we directly contacted national transplant
societies in these countries and responsible transplant
coordinators, and obtained their national and regional
DCD protocols (Table 2). If the information was not
complete, we were referred by the transplant societies to
specific transplant centers and responsible representa-
tives. Information of recent publications, the database
from the Transplant Procurement Management organi-
zation and published national consensus meetings was
used to further complete the information. From theseTable 1 Maastricht classification of donors after
circulatory death
Category Description Procurement
I Dead on arrival Uncontrolled
II Unsuccessful resuscitation Uncontrolled
III Awaiting cardiac arrest Controlled
IV Cardiac arrest while brain dead Uncontrolleddata, we compared the national strategies in DCD dona-
tion, including inclusion and exclusion criteria for DCD
donation, legislation, determination of death and preser-
vation methods. The study was performed in agreement
with the code of conduct on the use of data in health
research, put forward by the Dutch Federation of Biomedical
Scientific Societies [13].
Results
Ten countries in Europe actively perform DCD, of which
eight have specific protocols for DCD or describe DCD
procedures in one general protocol for organ donation.
Latvia and Czech Republic have no specific description
of DCD donation mentioned in their protocol. In four
countries (Italy, Austria, Latvia, Czech Republic), DCD
activity is restricted to one or two hospitals. In the
Netherlands and the UK, DCD donation is possible in
almost every hospital. Ten other countries are planning
to start a DCD program in the near future, including
Cyprus, Estonia, Luxembourg, Norway, Poland, Portugal,
Romania, Slovak Republic, Slovenia and Sweden. In seven
countries (Finland, Germany, Greece, Bosnia-Herzegovina,
Hungary, Lithuania, Turkey) there is no planned DCD
activity, mainly because of legal restriction. The most
important reason for not performing DCD next to legis-
lation includes organizational difficulties [12].
Table 3 summarizes the donor registration system, the
DCD categories used for donation and the organs pro-
cured from DCD donors in different European countries.
Reasons to explain the absence of controlled DCD dona-
tion (Maastricht category III) were ethical and juridical
restraints (France, Spain, Latvia); uncontrolled DCD
(Maastricht category I and II) was often not performed
because of organizational difficulties.
Inclusion and exclusion criteria
Out of the 10 countries with DCD, seven countries
(70%) described inclusion and exclusion criteria of con-
trolled and/or uncontrolled donation. Seven countries
actively performed controlled as well as uncontrolled
DCD (Spain, France and Latvia only uncontrolled DCD),
of which four separated inclusion and exclusion criteria
for controlled and uncontrolled donation in their proto-
cols, which mainly included differences in donor age
limits. Inclusion criteria for donation generally included
positive registration as a donor or permission of the next
of kin if a donor had not been registered with a donor
registry, witnessed arrest (in uncontrolled DCD) and age
limits. The most commonly used exclusion criteria were
hypothermia, intoxication, malignancy, sepsis (untreated)
and organ-specific contra-indications such as renal fail-
ure and liver cirrhosis. Next to the internationally used
Maastricht DCD categories, Spain and Italy describe
additional categories that include donation after sudden
Table 2 National authorities for organ donation and responsible organizations for organ allocation in different
countries
Country National authority for organ donation Responsible organization for organ allocation
Austria Österreichisches Bundesinstitut für Gesundheitswesen (ÖBIG) Eurotransplant
[http://www.goeg.at]
Belgium Belgische Transplantatie Vereniging/Société Belge de
Transplantation/Belgian Transplant Society (BTS)
Eurotransplant
[http://www.transplant.be]
Czech Republic Koordinační Středisko Transplantací (KST) Koordinační Středisko Transplantací
[http://www.kst.cz]
France Agence de la Biomédecine Agence de la Biomédecine
[http://www.agence-biomedecine.fr]
Italy Centro Nazionale Trapianti (CNT) Centro Nazionale Trapianti
[http://www.trapianti.salute.gov.it]
Latvia BaltTransplant – Latvian subdivision BaltTransplant
[http://www.stradini.lv]
The Netherlands Nederlandse Transplantatie Stichting (NTS) Eurotransplant
[www.transplantatiestichting.nl]
United Kingdom National Health Service Blood and Transplant (NHSBT) National Health Service Blood and Transplant
[http://www.nhsbt.nhs.uk]
Spain Organización National de Trasplantes (ONT) Organización National de Trasplantes
[http://www.ont.es]
Switzerland Swiss Transplant Swiss Transplant
[http://www.swisstransplant.org]
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during extracorporeal membrane oxygenation (Italy). In
most countries DCD donors are predominantly Maastricht
category III donors – that is, donors who die after with-
drawal of treatment – which results in a high percentageTable 3 Registration system, donation after circulatory







Austria Opt out II, III Kidneys
Belgium Opt out II, III, IVa Kidney, liver,
pancreas, lungsa
Czech Republic Opt out I,II, III, IV Kidneys
France Opt out I, II, IV Kidneys
Italy Opt out II, III, IV Kidneys
Latvia Opt out II, IV Kidneys
The Netherlands Opt in II, III, IV Kidneys, liver,
pancreas, lungs
United Kingdom Opt in II, III, IV Kidneys, liver,
pancreas, lungsa
Spain Opt out I,II,IVa Kidney, liver, lungs
Switzerland Opt in I,II,III,IV Kidney, liver, lungs
DCD, donation after circulatory death. aVariation in regional protocols.of DCD donors in the UK, the Netherlands and Belgium
(Table 4). France performs only uncontrolled DCD.
Spain recently performed its first controlled DCD, after
many years of successful uncontrolled DCD.Legislation
In all countries with a donor protocol, there was an
organ donation law. Although the actual donation act
was often not included in the protocol, a reference was
always available. Three out of 10 countries (30%)
performing DCD in Europe have an opt-in registration
system; this means that explicit consent for donation is
necessary by donor card or registration in a national
registry (Table 3). In the other seven countries (70%)
with a DCD program, presumed consent is used; explicit
consent for donation is not required but is presumed if
the person has not objected during life.Opt-in registration
There are three countries with a DCD program and an
opt-in registration system (the UK, the Netherlands and
Switzerland). In the Netherlands and Switzerland, regis-
tration as a donor is sufficient to proceed to organ pro-
curement, and the relatives are informed. In the UK, the
opt-in registration system requires additional consent by
Table 4 Absolute numbers and percentage of DCD donors in 2011 and 2012 in different countries
Country Actual DCD donors Percentage of DCD donors from




2011 2012 2011 2012 2011 2012
Austria 6 4 3 2 23.2 22.5 1994
Belgium 61 70 19 19 29.3 32.9 1994
Czech Republic 1 2 <1 1 17.6 19.8 2002
France 58 n/a 4 n/a 25.0 n/a 2006
Italy 6 5 <1 1 21.9 22.4 2005
Latvia 13 23 32 60 17.9 19.0 1992
The Netherlands 111 124 50 49 13.2 15.0 1981
United Kingdom 405 n/a 38 n/a 17.0 n/a 1989
Spain 117 161 7 10 35.3 34.8 1989
Switzerland 3 7 3 7 12.8 12.0 1993
Absolute numbers and percentage of DCD donors of the total number of deceased donors in 2011 and 2012 in different countries. DCD, donation after circulatory
death; PMP, percentage per million population.
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ways excludes organ donation.
All three protocols allow use of in situ preservation
(ISP) in uncontrolled DCD donors to preserve organs if
a person has not objected to donation. ISP is a minim-
ally invasive technique to preserve the organs after de-
termination of death and a no-touch period. A special
catheter with proximal and distal occlusion balloons is
inserted through the femoral artery into the aorta, which
enables selective flushing of the kidneys. ISP preserves
organ viability and provides the opportunity to meet
legal and logistical requirements before organ procure-
ment. ISP also gives relatives time to decide about organ
donation.
Opt-out registration
Seven countries use the system of presumed consent for
donation. Six out of seven protocols require additional
permission from the next of kin; Spain requires written
permission. Austria does not specify informed consent
of the relatives in its protocol. In clinical practice, in
most countries with an opt-out system, the relatives are
consulted to confirm the consent for donation. In Latvia,
the next of kin has to submit their objection in writing if
there is no information in the donor registry. In uncon-
trolled donors, most protocols allow ISP awaiting the
relatives’ consent. In Spain, approval has to be requested
from the local court. In most countries, it is allowed or
otherwise not specifically mentioned in the protocol for
controlled donors, to maintain or optimise the condition
of the potential donor after the decision has been made
to withdraw treatment if this does not harm the patient
or cause discomfort. In Switzerland, (opt-in) consent of
the next of kin is required before starting any medical
treatment to improve the condition of the donor.Determination of death
The description of how death is determined varied in
the protocols; from no description at all, or referring to
standard criteria (the so-called lege artis), to more
specific guidelines and tests that have to be performed
(Table 5). Some protocols refer to guidelines or proto-
cols for the determination of death [14,15]. The
standard criteria to determine death after cessation
of medical treatment of a DCD donor refer to
cardiocirculatory criteria: irreversible cessation of circu-
latory and respiratory function. Diagnostic procedures
used to confirm death differ among protocols; absent
intra-arterial pressure, isoelectric electrocardiogram,
absent cardiac function on echocardiogram (Table 4).
All protocols describe an observation period after cir-
culatory arrest – the no-touch time, the period of time
during which no interventions are performed in the
donor. However, this period is described differently: as
the observation period between the circulatory arrest
and the determination of death, or as the time period
between determination of death and initiation of organ
procurement. The no-touch time differs from 5 to 20
minutes (Table 5). In Italy, 20 minutes of an isoelectric
electrocardiogram registration is necessary very
difficult.
Separation of the team responsible for the treatment
of the patient and the organ procurement team is men-
tioned in all protocols. In Spain and France, the poten-
tial uncontrolled donor is recognized by the ambulance
service and, after unsuccessful resuscitation, treated as
a potential donor with continuation of chest compres-
sions, ventilation and fluid perfusion. Only after arrival
at the hospital does the attending physician determine
death of the patient and the procurement team starts
the donor procedure.
Table 5 Items described in the protocols
Country Criteria for determination of death
and diagnostic procedures
Death determined by No-touch time
(minutes)
Preservation method
Austria Asystole, not specified Treating physician with
jus practicandi
10 Laparotomy with direct
cannulation
Belgium Cardiorespiratory criteria, according to
most recent standarda
Three independent physicians 5 Laparotomy with direct
cannulation
Czech Republicb Not described Independent physician, not
involved in donation
10 DBTL catheter
France Cardiorespiratory criteria, unconsciousness,
absence of brainstem reflexes. ECG
Independent physician, not
involved in donation
5 nECMO, DBTL catheter
Italy Asystole, isoelectric ECG to confirm Treating physician 20 nECMO
Latviab Not described Intensivist 15 Laparotomy with
direct cannulation, DBTL catheter
The Netherlands Cardiocirculatory arrest, not specified Treating physician 5 Laparotomy with direct
cannulation, DBTL catheter
United Kingdoma Cardiocirculatory arrest, unconsciousness.
Intra-arterial pressure monitoring, ECG
during 5 minutes. After 5 minutes, absence
of brainstem reflexes confirmed
Treating physician 5 Laparotomy with direct
cannulation, DBTL catheter
Spain Asystole, apnea, no response to stimuli.
ECG to confirm
Treating physician 5 ECMO, nECMO, DBTL catheter
Switzerland Lege artis, referred to specific guidelines,
TTE to confirm asystole
Two independent physicians 10 Laparotomy with direct
cannulation
DBTL, double balloon, triple lumen; ECG, electrocardiogram; ECMO, extracorporeal membrane oxygenation; nECMO, normothermic extracorporeal membrane
oxygenation; TTE, transthoracic echocardiogram.
aVariation in regional protocols. bDonation after circulatory death not described in a protocol.
Wind et al. Critical Care 2013, 17:R217 Page 5 of 7
http://ccforum.com/content/17/5/R217Preservation methods
The most commonly used preservation method for con-
trolled DCD donation is rapid laparotomy with cannula-
tion of the abdominal aorta [16]. After death in the ICU,
the deceased is taken to the operating room. In uncon-
trolled donors, ISP with the double-balloon, triple-lumen
catheter or the Gillot catheter is used. In the two countries
with the largest numbers of uncontrolled donors (Spain
and France), extracorporeal membrane oxygenation with
either hypothermic or normothermic perfusion is used as
the preservation method of choice.
Discussion
There is a relatively large variability in European DCD
protocols. This can be expected, because legislation, ex-
pertise, experience and organizational factors differ. Espe-
cially uncontrolled DCD requires specific organization,
because the donation procedure is always unexpected.
The time between the determination of death and preser-
vation of the organs is important, to minimize warm is-
chemic time and organ injury. The way in which DCD
procedures are described varies, from no specific protocol
(two countries) to detailed protocols with complementary
consensus statements and ethical frameworks, as in the
UK [17].
Reasons for not performing DCD at all include con-
flicts with national law or difficulties with the infrastruc-
ture to initiate a DCD program [12]. Also, reluctance toexplore the possibilities within the law to perform DCD
can play a role. Countries that perform DCD differ in
the percentage of DCD transplantations compared with
the total numbers of deceased donors, and the use of
different Maastricht categories. Some countries focus on
uncontrolled DCD (Spain, France), and others focus on
controlled DCD (the Netherlands, the UK) or perform
both. The difference can be explained by practice in
ICUs to withdraw life-sustaining treatment or not. In
northern European countries, withdrawal of treatment, if
treatment is considered futile, is a more accepted prac-
tice than in southern European countries [18]. These dif-
ferences may partly be caused by the availability of
intensive care capacity, which may force doctors towards
less expectative approach to discontinue useless medical
treatment.
A notable difference between protocols is the way in
which death of the patient is determined. When a de-
ceased patient is an eligible organ donor, both the accurate
determination of death and a fast transition from treating
a patient to preserving a donor is essential to enable organ
preservation with minimized ischemic injury to the or-
gans. Definitions of the criteria to determine death and
the no-touch period, to ensure irreversibility of cardio-
circulatory arrest, are therefore crucial. Determination of
death varies in the different protocols, but also between
ICUs. There is a lack of uniformity [19-21]. This includes
the definition of death, the tests used to determine death
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gans can be procured. Different definitions have important
implications for donor treatment and end-of-life care, but
also for the ischemic period of the organs and organ via-
bility. With the expansion of DCD programs, the lack of
consensus about determination of death is a point of dis-
cussion and concern [22-24]. It is important to have clear,
uniform and consistent evidence-based guidelines to de-
termine death, in order to fulfill medical, ethical and legal
obligations and to ensure public trust [19].
Donor procurement strategies differ throughout Europe,
and the implementation of protocols differs even more.
Strategies to procure organs each have their advantages
and disadvantages and depend on consent systems, legal
opportunities, in-hospital and out-of-hospital institution
and financial possibilities. Protocols can be helpful to ob-
tain and maintain support for DCD programs and to help
other institutes or countries to develop, implement and
continue DCD. The protocols also provide answers to im-
portant ethical questions concerning end-of-life manage-
ment and care [25].
Conclusion
DCD is an established strategy to enlarge the donor pool
and to contribute to the reduction of the waiting list for
transplantation. The DCD potential in Europe is not yet
fully utilized. DCD protocols in European countries and
even in individual hospitals are heterogeneous. Restric-
tions by national laws, organizational problems or eth-
ical struggles are important factors for this. Following
these conclusions, we feel it is important that experi-
ences with DCD are shared and consensus is obtained,
so these can be translated into more uniform and solid
protocols supported by the competent authorities, trans-
plant and intensive care professionals, which may eventu-
ally result in a further promotion of DCD transplantation
in Europe.
Key messages
 Transplantation of organs from donors after
circulatory death (DCD) contributes to the
reduction of the waiting list for transplantation,
but the DCD potential in Europe is not yet fully
utilized.
 There is a large variability within European
countries to perform DCD and existing DCD
protocols are heterogeneous.
 Protocols can be helpful to develop, implement and
improve DCD performance and answer ethical
questions.
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